Differentiated approach to management of patients with irritable bowel syndrome and ulcerative colitis in non-alcoholic fatty liver disease.

Objective: Aim: To determine the main clinical and laboratory features and severity of colon dysbiosis in irritable bowel syndrome (IBS) and IBD in patients with NAFLD.

Patients And Methods: Materials and Methods: 80 patients with NAFLD were examined. Patients were divided into two groups.

CORRECTION OF AUTONOMIC AND COGNITIVE DISTURBANCES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE.

Objective: The aim: To explore the features of the congnitive (CD) and neurovegetative dysfunctions (NVD) of patients with different forms of non-alcoholic fatty liver disease NAFLD (nonalcoholicfatty hepatosis (NAFH) and non-alcoholic steatohepatitis (NASH)) and type 2 diabetes mellitus (T2DM), as well as their dynamics against the background of complex therapy using armadin (2-ethyl-6-methyl-3-hydroxypyridine succinate).

Patients And Methods: Materials and methods: 50 patients with NAFLD (24 patients with NAFH and 26 patients with NASH) and T2DM were examined. Dysfunction of central and vegetative nervous system was carried out with the help of neuro-psychometric testing.

Changes in the level of α1-antitrypsin in patients with non-alcoholic fatty liver disease.

Objective: The aim: To investigate changes in the level of α1-antitrypsin (A1AT) in blood and in stool and their diagnostic value in patients with NAFLD and with impaired carbohydrate metabolism at different stages of liver damage.

Patients And Methods: Materials and methods: 34 patients with non-alcoholic fatty hepatosis (NAFH) and 40 patients with non-alcoholic steatohepatitis (NASH) were examined. Enzyme-linked immunosorbent assay for all patients with serum and coli was performed by determining the level of A1AT.